Pfizer’s bet on bispecific antibodies gets a spookily timely endorsement from Nature Review Drug Discovery!

Pfizer’s bet on bispecific antibodies gets a spookily timely endorsement from Nature Review Drug Discovery!

No sooner had my excitement over Pfizer’s tell-all oncology strategy on their 29th February 2024 innovation day abated from last week, then I get another follow-on burst of excitement this week!  You may recall in my blog last week that Pfizer revealed they intended to get at least 8 oncology blockbusters by 2030.  This is an absolutely huge ambition and huge target and so, how are they going to achieve this?  By specifically zooming in on 3 modalities – 1) small molecules,  2) ADCs and 3) Bispecific Antibodies.  You will already know how fond I am of ADCs, as this is an area that is already bursting with scientific and clinical activity.

What about bispecifics?  Well, just a week on from the Pfizer innovation day,  Nature Reviews Drug Discovery published a brilliant review on ‘The present and future of bispecific antibodies for cancer therapy’.  Is this review spookily timely or what?  Or is Nature Reviews Drug Discovery in cahoots with Pfizer? 😂.  I’d like to say ‘Great minds think alike‘ and I’d definitely recommend reading this review and getting excited about what bispecifics might come out from the Pfizer engine-house in the near future.

READ THE ARTICLE – https://www.nature.com/articles/s41573-024-00896-6

 

Share this post